on INVENTIVA (EPA:IVA)
Inventiva Announces Preliminary Financial Results for 2024
Inventiva has released its preliminary financial results for the year 2024. Revenues amounted to €9.2 million, while cash reached €96.6 million as of December 31, 2024. The company raised a first tranche of structured financing totaling €116 million.
In terms of research, the last patient for Phase 3 of the NATiV3 study on lanifibranor was screened in early 2025. The company has decided to reorient its strategy, focusing exclusively on the development of lanifibranor and reducing staff by 50%.
R&D expenses decreased by 17% in 2024, reaching €90.9 million, mainly due to the pause in patient recruitment for the NATiV3 study. A restart of these activities is planned in 2025.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all INVENTIVA news